NewAmsterdam Pharma says EU grants approval for obicetrapib cholesterol drugs Ubeslo, Evlarco
NAMS•EU approves first obicetrapib therapies
The European Commission granted marketing authorization for Ubeslo and Evlarco, obicetrapib-based LDL-C therapies, marking the first global approval for obicetrapib.
The approval covers primary hypercholesterolaemia, including HeFH, non-familial disease, or mixed dyslipidaemia.
Partner Menarini holds exclusive commercialization rights in Europe; NewAmsterdam is eligible for double-digit royalties and up to €833 million in milestones.
